Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Sarcopenia, Sarcopenic Obesity and Osteosarcopenic Obesity in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04122638
Recruitment Status : Recruiting
First Posted : October 10, 2019
Last Update Posted : October 10, 2019
Sponsor:
Collaborators:
Istanbul Medeniyet University
Istanbul University
Information provided by (Responsible Party):
Filiz Demirdağ, Goztepe Training and Research Hospital

Brief Summary:
Syndromes such as sarcopenia, sarcopenic obesity and osteosarcopenic obesity are commonly seen in older adults. They result from the impairment of muscle, bone and adipose tissue. Thus, they lead to a decrease in quality of life and increase morbidity and mortality. The aim of this study is to report the prevalence of sarcopenia, sarcopenic obesity and osteosarcopenic obesity in community-dwelling outpatient older adults and to investigate the related factors.

Condition or disease
Sarcopenia Sarcopenic Obesity Osteopenia, Osteoporosis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prevalence of Sarcopenia, Sarcopenic Obesity and Osteosarcopenic Obesity in Community-dwelling Outpatient Older Adults
Actual Study Start Date : October 7, 2019
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2020



Primary Outcome Measures :
  1. Handgrip Strength [ Time Frame: 10 minutes ]
    Handgrip strength measured by Takei© Hand Dynamometer

  2. Muscle mass [ Time Frame: 5 minutes ]
    Using Bioimpedance analysis (BİA) technique with TANITA© TBF 300

  3. Bone density [ Time Frame: 30 minutes ]
    T score evaluation using Dual-energy X-ray absorptiometry (DEXA)

  4. Percentage of body fat [ Time Frame: 5 minutes ]
    Using Bioimpedance analysis (BİA) technique with TANITA© TBF 300


Secondary Outcome Measures :
  1. Gait speed [ Time Frame: 3 minutes ]
    4-m usual walking speed test

  2. Physical Activity [ Time Frame: 5-10 minutes ]
    Using Rapid Assessment of Physical Activity (RAPA)

  3. Nutritional Status [ Time Frame: 10 minutes ]
    Assessed with Mini-Nutritional Assessment (MNA)

  4. Activities of Daily Living [ Time Frame: 10 minutes ]
    Activities of daily living assessed with Katz Index of Independence in Activities of Daily Living

  5. Instrumental Activities of Daily Living [ Time Frame: 10 minutes ]
    Instrumental activities of daily living assessed with Lawton -Brody Instrumental Activities of Daily Living Scale

  6. Depression [ Time Frame: 10 minutes ]
    Assessed with The Geriatric Depression Scale- Short Form

  7. Mini-Mental State Examination [ Time Frame: 10-15 minutes ]
    Mini-Mental State Examination

  8. Blood Sample Analysis [ Time Frame: 5 minutes ]
    A blood sample analysis including parameters such as: wbc, hgb, htc, mcv ,plt, fasting blood sugar, urea, uric acid, creatin, AST, ALP, ALT, GGT, LDH, total colesterol, trigylicerid, LDL, HDL, NA, K, Mg, Ca, P, Albumin, protrombin time, CRP, B12, folate, iron, ferritin, PTH, vitamin-D, sedimentation, TSH, T4, insukin, HGBA1C, IHOMA-IR.

  9. Comorbidities [ Time Frame: 5 minutes ]
    Assessed with Charlson Comorbidity Index



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Community-dwelling older adults
Criteria

Inclusion Criteria:

  • Being at the age of 65 or older
  • Being able to complete 4-m walk test

Exclusion Criteria:

  • <24 points on Mini-Mental State Examination
  • 12 points or higher on Geriatric Depression Scale

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04122638


Contacts
Layout table for location contacts
Contact: Filiz Demirdağ, MD +90(216) 566 40 00 filizakcay@gmail.com

Locations
Layout table for location information
Turkey
Goztepe Training and Research Hospital Recruiting
Istanbul, Turkey, 34722
Contact: Filiz Demirdağ, MD       filizakcay@gmail.com   
Sponsors and Collaborators
Goztepe Training and Research Hospital
Istanbul Medeniyet University
Istanbul University

Layout table for additonal information
Responsible Party: Filiz Demirdağ, Principal Investigator, Goztepe Training and Research Hospital
ClinicalTrials.gov Identifier: NCT04122638     History of Changes
Other Study ID Numbers: GoztepeTRH
First Posted: October 10, 2019    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Keywords provided by Filiz Demirdağ, Goztepe Training and Research Hospital:
Older adults
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis
Bone Diseases, Metabolic
Sarcopenia
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical